Savara Inc Debt Securities, Available-for-sale, Amortized Cost
Savara Inc (SVRA) had Debt Securities, Available-for-sale, Amortized Cost of $131.28 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $131.28M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $164.00M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $202.29M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $107.99M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $131.28M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $164.00M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $202.29M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $107.99M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $129.01M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $152.86M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $180.96M 10-K · filed 2026-03-13 |
| 2024-09-30 | $197.51M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $97.74M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $126.32M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $135.54M 10-K · filed 2025-03-27 |
| 2023-09-30 | $140.62M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $82.49M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $80.79M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $73.78M 10-K · filed 2024-03-07 |
| 2022-09-30 | $14.28M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $47.40M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $72.71M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $127.21M 10-K · filed 2023-03-30 |
| 2021-09-30 | $126.12M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $140.02M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $136.76M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $59.31M 10-K · filed 2022-03-30 |
| 2019-12-31 | $71.91M 10-K · filed 2021-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |